(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...

Largest ever protein study set to revolutionise cancer and dementia tests - Tens of millions of pounds in investment is being ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...

Discover a groundbreaking study that may help detect Alzheimer's in its early stages. Learn about the link between blood ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

A chronic gut infection caused by a common virus may be linked to the progression of Alzheimer ’s disease, a new study has ...